** Shares of Australia's LTR Pharma LTP.AX rise as much as 10.4% to A$0.425, their highest levels since May 2
** The biopharmaceutical firm signs a collaborative agreement with Strategic Drug Solutions
** The agreement is to co-develop OROFLOW, a novel intranasal spray targeting Oesophageal Motility Disorders - a group of conditions that cause impaired swallowing
** Stock has fallen 52.5% so far this year
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。